Eric Miele
AstraZeneca (South Korea)(KR)AstraZeneca (United States)(US)
Publications by Year
Research Areas
Advanced Proteomics Techniques and Applications, Epigenetics and DNA Methylation, Cancer-related Molecular Pathways, Ubiquitin and proteasome pathways, Peptidase Inhibition and Analysis
Most-Cited Works
- → Compounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance(2022)34 cited
- → Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles(2018)22 cited
- → Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods(2021)14 cited
- → Proteomics of prostate cancer serum and plasma using low and high throughput approaches(2024)7 cited
- → DOSCHEDA: a web application for interactive chemoproteomics data analysis(2017)4 cited
- → Abstract LB008: Integrative dynamic MultiOMICs analysis identifies cell cycle and DNA damage response phenotypes as downstream consequences of using the PRMT5 inhibitor AZD3470(2024)3 cited
- → Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition(2024)2 cited
- → Affi-BAMS™: A Robust Targeted Proteomics Microarray Platform to Measure Histone Post-Translational Modifications(2023)1 cited
- → Mass Spectrometry and Chemical Biology Approaches for Deconvoluting Epigenetic Targets(2024)
- → Abstract 7089: Proteomic evaluation of combination data in acute myeloid leukemia to inform mechanism of action and new targets(2024)